-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Downgrades Alnylam Pharmaceuticals to Outperform, Lowers Price Target to $315

Benzinga·10/30/2026 10:01:43
Listen to the news
Raymond James analyst Martin Auster downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Strong Buy to Outperform and lowers the price target from $420 to $315.